Therapeutic dsRNA for Exercise Tolerance in ME/CFS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are ineffective in improving exercise tolerance and quality of life for a significant portion of patients, particularly those with symptoms lasting between 2 to 8 years, as they do not address the underlying pathogenic mechanisms effectively.
Innovation Solution
Administration of a therapeutic double-stranded RNA (dsRNA) composition, specifically rintatolimod or mismatched dsRNA, to ME/CFS patients with symptom onset between 2 to 8 years, which increases exercise tolerance by at least 25% and improves quality of life, administered via various routes including intravenous, buccal, and inhalation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for ME/CFS patients, then treatment is provided, but exercise tolerance is not significantly improved
Solution Approach 1:
The patent identifies and utilizes the parameter of symptom duration (2-8 years) as a key stratification criterion to identify patients who are most likely to respond to dsRNA therapy. This parameter-based stratification enables selective treatment of the responsive subpopulation, transforming conventional ineffective treatments into effective interventions for the identified target group.
Solution Approach 2:
The patent employs feedback mechanisms through clinical trial data analysis to identify responsive patient subpopulations based on symptom duration and other characteristics. This feedback loop allows for iterative refinement of treatment criteria and patient selection, improving treatment effectiveness over time.
2Reliability
If therapeutic dsRNA is administered to ME/CFS patients with 2-8 year symptom onset, then exercise tolerance increases by at least 25%, but treatment complexity and monitoring requirements increase
Solution Approach 1:
The patent segments the ME/CFS patient population into distinct subgroups based on symptom duration (2-8 years vs. other durations). This segmentation allows for tailored treatment approaches, where dsRNA therapy is selectively applied to the segment most likely to benefit, thereby improving overall treatment effectiveness while managing complexity through focused application.
Solution Approach 2:
The patent performs preliminary identification and stratification of patients based on symptom duration and other predictive factors before initiating dsRNA therapy. This preliminary action ensures that only the most suitable candidates receive treatment, optimizing the balance between treatment benefits and monitoring requirements.
3Adaptability or versatility
If dsRNA therapy is administered to all ME/CFS patients, then treatment coverage is maximized, but treatment effectiveness decreases due to lack of patient selection
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to specific patient subgroups with distinct characteristics (symptom duration 2-8 years). Rather than applying a uniform treatment to all patients, the therapy is localized to the subpopulation most likely to respond, thereby maintaining high effectiveness while expanding coverage to this identifiable group.
Solution Approach 2:
The patent utilizes parameter changes in patient characteristics (specifically symptom duration) to determine treatment eligibility. By changing the selection criteria based on measurable parameters, the patent achieves both broad coverage for the identified subpopulation and high treatment effectiveness, resolving the contradiction between coverage and effectiveness.
Data Source
AI summary
The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).